161 related articles for article (PubMed ID: 1346975)
1. Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX.
Ludwig M; Sabharwal AK; Brackmann HH; Olek K; Smith KJ; Birktoft JJ; Bajaj SP
Blood; 1992 Mar; 79(5):1225-32. PubMed ID: 1346975
[TBL] [Abstract][Full Text] [Related]
2. Factor IXHollywood: substitution of Pro55 by Ala in the first epidermal growth factor-like domain.
Spitzer SG; Kuppuswamy MN; Saini R; Kasper CK; Birktoft JJ; Bajaj SP
Blood; 1990 Oct; 76(8):1530-7. PubMed ID: 2169923
[TBL] [Abstract][Full Text] [Related]
3. Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme.
Bajaj SP; Spitzer SG; Welsh WJ; Warn-Cramer BJ; Kasper CK; Birktoft JJ
J Biol Chem; 1990 Feb; 265(5):2956-61. PubMed ID: 2303434
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
Lin SW; Lin CN; Hamaguchi N; Smith KJ; Shen MC
Blood; 1994 Sep; 84(6):1866-73. PubMed ID: 7915915
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
[TBL] [Abstract][Full Text] [Related]
6. Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
Miyata T; Kuze K; Matsusue T; Komooka H; Kamiya K; Umeyama H; Matsui A; Kato H; Yoshioka A
Br J Haematol; 1994 Sep; 88(1):156-65. PubMed ID: 7803238
[TBL] [Abstract][Full Text] [Related]
7. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain.
Bajaj SP; Sabharwal AK; Gorka J; Birktoft JJ
Proc Natl Acad Sci U S A; 1992 Jan; 89(1):152-6. PubMed ID: 1729682
[TBL] [Abstract][Full Text] [Related]
8. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
Larson PJ; Stanfield-Oakley SA; VanDusen WJ; Kasper CK; Smith KJ; Monroe DM; High KA
J Biol Chem; 1996 Feb; 271(7):3869-76. PubMed ID: 8632006
[TBL] [Abstract][Full Text] [Related]
9. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
[TBL] [Abstract][Full Text] [Related]
10. A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
Taylor SA; Liddell MB; Peake IR; Bloom AL; Lillicrap DP
Br J Haematol; 1990 Jun; 75(2):217-21. PubMed ID: 2372509
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.
Hamaguchi N; Roberts H; Stafford DW
Biochemistry; 1993 Jun; 32(25):6324-9. PubMed ID: 8518277
[TBL] [Abstract][Full Text] [Related]
12. Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities.
Miyata T; Sakai T; Sugimoto M; Naka H; Yamamoto K; Yoshioka A; Fukui H; Mitsui K; Kamiya K; Umeyama H
Biochemistry; 1991 Nov; 30(47):11286-91. PubMed ID: 1958666
[TBL] [Abstract][Full Text] [Related]
13. Factor IX Chongqing: a new mutation in the calcium-binding domain of factor IX resulting in severe hemophilia B.
Wang NS; Zhang M; Thompson AR; Chen SH
Thromb Haemost; 1990 Feb; 63(1):24-6. PubMed ID: 2339358
[TBL] [Abstract][Full Text] [Related]
14. A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver.
Geddes VA; Le Bonniec BF; Louie GV; Brayer GD; Thompson AR; MacGillivray RT
J Biol Chem; 1989 Mar; 264(8):4689-97. PubMed ID: 2494175
[TBL] [Abstract][Full Text] [Related]
15. A factor IX mutation, verified by direct genomic sequencing, causes haemophilia B by a novel mechanism.
Tsang TC; Bentley DR; Mibashan RS; Giannelli F
EMBO J; 1988 Oct; 7(10):3009-15. PubMed ID: 3181127
[TBL] [Abstract][Full Text] [Related]
16. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
[TBL] [Abstract][Full Text] [Related]
17. Expression and characterization of human factor IX. Factor IXthr-397 and factor IXval-397.
Hamaguchi N; Charifson PS; Pedersen LG; Brayer GD; Smith KJ; Stafford DW
J Biol Chem; 1991 Aug; 266(23):15213-20. PubMed ID: 1907972
[TBL] [Abstract][Full Text] [Related]
18. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
Nishimura H; Takeya H; Miyata T; Suehiro K; Okamura T; Niho Y; Iwanaga S
J Biol Chem; 1993 Nov; 268(32):24041-6. PubMed ID: 8226948
[TBL] [Abstract][Full Text] [Related]
19. Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
Maekawa H; Sugo T; Yamashita N; Kamiya K; Umeyama H; Miura N; Naka H; Nishimura T; Yoshioka A; Matsuda M
Biochemistry; 1993 Jun; 32(24):6146-51. PubMed ID: 8512923
[TBL] [Abstract][Full Text] [Related]
20. Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.
Chen SH; Thompson AR; Zhang M; Scott CR
J Clin Invest; 1989 Jul; 84(1):113-8. PubMed ID: 2472424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
